Chk2*1100delC Acts in synergy with the Ron receptor tyrosine kinase to accelerate mammary tumorigenesis in mice

Cancer Letters

Volumn 296, Issue 2, 2010, Pages 186-193

  Meyer, Sara E ^a   Peace, Belinda E ^a   Bahassi, El Mustapha ^a   Kavanaugh, Gina M ^a   Wagh, Purnima K ^a   Robbins, Susan B ^a   Yin, Moying ^a   Wells, Susanne I ^a   Zinser, Glendon M ^a   Stambrook, Peter J ^a   Waltz, Susan E ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Breast cancer; CHEK2; Hepatocyte growth factor like protein (HGFL); Met receptor; MST1R; Receptor tyrosine kinase

Indexed keywords

CHECKPOINT KINASE 2; PROTEIN TYROSINE KINASE; RON RECEPTOR TYROSINE KINASE; UNCLASSIFIED DRUG; PROTEIN SERINE THREONINE KINASE; RON PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CELL CYCLE REGULATION; CONTROLLED STUDY; FEMALE; GENE ACTIVITY; GENE DELETION; GENE FREQUENCY; GENE OVEREXPRESSION; GROWTH ACCELERATION; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PENETRANCE; PRIORITY JOURNAL; ANIMAL; BREAST TUMOR; CELL CYCLE; CELL DIVISION; EXPERIMENTAL NEOPLASM; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; PATHOLOGY; RISK FACTOR; TUMOR CELL LINE;

MUS;

ANIMALS; BREAST NEOPLASMS; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; FEMALE; GENETIC VARIATION; HUMANS; IMMUNOHISTOCHEMISTRY; MAMMARY NEOPLASMS, ANIMAL; MICE; POLYMORPHISM, GENETIC; PROTEIN-SERINE-THREONINE KINASES; RECEPTOR PROTEIN-TYROSINE KINASES; RISK FACTORS; SEQUENCE DELETION;

EID: 77955276664     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.04.011     Document Type: Article

References (41)

1. Turnbull C., Rahman N. Genetic predisposition to breast cancer: past, present, and future. Ann. Rev. Genom. Hum. Genet. 2008, 9:321-345.
2. Ripperger T., Gadzicki D., Meindl A., Schlegelberger B. Breast cancer susceptibility: current knowledge and implications for genetic counselling. Eur. J. Hum. Genet. 2009, 17(6):722-731.
3. Bahassi el M., Penner C.G., Robbins S.B., et al. The breast cancer susceptibility allele CHEK2*1100delC promotes genomic instability in a knock-in mouse model. Mutat. Res. 2007, 616(1-2):201-209.
4. Meijers-Heijboer H., van den Ouweland A., Klijn J., et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat. Genet. 2002, 31(1):55-59.
5. Oldenburg R.A., Kroeze-Jansema K., Kraan J., et al. The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families. Cancer Res. 2003, 63(23):8153-8157.
6. Offit K., Garber J.E. Time to check CHEK2 in families with breast cancer?. J. Clin. Oncol. 2008, 26(4):519-520.
7. Iniesta M.D., Merajver S.D. CHEK2 screening: do not think so globally yet. J. Clin. Oncol. 2008, 26(18):3092. (Author reply 3093-3094).
8. Ahn J., Urist M., Prives C. The Chk2 protein kinase. DNA Repair (Amst) 2004, 3(8-9):1039-1047.
9. Bahassi el M., Myer D.L., McKenney R.J., Hennigan R.F., Stambrook P.J. Priming phosphorylation of Chk2 by polo-like kinase 3 (Plk3) mediates its full activation by ATM and a downstream checkpoint in response to DNA damage. Mutat. Res. 2006, 596(1-2):166-176.
10. Bartek J., Falck J., Lukas J. CHK2 kinase-a busy messenger. Nat. Rev. Mol. Cell Biol. 2001, 2(12):877-886.
11. Falck J., Mailand N., Syljuasen R.G., Bartek J., Lukas J. The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 2001, 410(6830):842-847.
12. McGowan C.H. CHK2: a tumor suppressor or not?. Cell Cycle 2002, 1(6):401-403.
13. Takai H., Naka K., Okada Y., et al. Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. Embo. J. 2002, 21(19):5195-5205.
14. Hirao A., Kong Y.Y., Matsuoka S., et al. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science 2000, 287(5459):1824-1827.
15. Hirao A., Cheung A., Duncan G., et al. Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol. Cell. Biol. 2002, 22(18):6521-6532.
16. Bahassi el M., Robbins S.B., Yin M., et al. Mice with the CHEK2*1100delC SNP are predisposed to cancer with a strong gender bias. Proc. Natl. Acad. Sci., USA 2009, 106(40):17111-17116.
17. Ronsin C., Muscatelli F., Mattei M.G., Breathnach R. A novel putative receptor protein tyrosine kinase of the met family. Oncogene 1993, 8(5):1195-1202.
18. Wang M.H., Iwama A., Skeel A., Suda T., Leonard E.J. The murine stk gene product, a transmembrane protein tyrosine kinase, is a receptor for macrophage-stimulating protein. Proc. Natl. Acad. Sci., USA 1995, 92(9):3933-3937.
19. Wang M.H., Ronsin C., Gesnel M.C., et al. Identification of the ron gene product as the receptor for the human macrophage stimulating protein. Science 1994, 266(5182):117-119.
20. Gaudino G., Follenzi A., Naldini L., et al. RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP. Embo. J. 1994, 13(15):3524-3532.
21. Wang M.H., Lee W., Luo Y.L., Weis M.T., Yao H.P. Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cells. J. Pathol. 2007, 213(4):402-411.
22. Camp E.R., Liu W., Fan F., Yang A., Somcio R., Ellis L.M. RON, a tyrosine kinase receptor involved in tumor progression and metastasis. Ann. Surg. Oncol. 2005, 12(4):273-281.
23. O'Toole J.M., Rabenau K.E., Burns K., et al. Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member. Cancer Res. 2006, 66(18):9162-9170.
24. Maggiora P., Marchio S., Stella M.C., et al. Overexpression of the RON gene in human breast carcinoma. Oncogene 1998, 16(22):2927-2933.
25. Waltz S.E., Eaton L., Toney-Earley K., et al. Ron-mediated cytoplasmic signaling is dispensable for viability but is required to limit inflammatory responses. J. Clin. Invest. 2001, 108(4):567-576.
26. Peace B.E., Toney-Earley K., Collins M.H., Waltz S.E. Ron receptor signaling augments mammary tumor formation and metastasis in a murine model of breast cancer. Cancer Res. 2005, 65(4):1285-1293.
27. Zinser G.M., Leonis M.A., Toney K., et al. Mammary-specific Ron receptor overexpression induces highly metastatic mammary tumors associated with beta-catenin activation. Cancer Res. 2006, 66(24):11967-11974.
28. Meyer S.E., Zinser G.M., Stuart W.D., Pathrose P., Waltz S.E. The Ron receptor tyrosine kinase negatively regulates mammary gland branching morphogenesis. Dev. Biol. 2009, 333(1):173-185.
29. Rogakou E.P., Pilch D.R., Orr A.H., Ivanova V.S., Bonner W.M. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J. Biol. Chem. 1998, 273(10):5858-5868.
30. Roh M., Franco O.E., Hayward S.W., van der Meer R., Abdulkadir S.A. A role for polyploidy in the tumorigenicity of Pim-1-expressing human prostate and mammary epithelial cells. PLoS ONE 2008, 3(7):e2572.
31. Elledge S.J. Cell cycle checkpoints: preventing an identity crisis. Science 1996, 274(5293):1664-1672.
32. Bell D.W., Varley J.M., Szydlo T.E., et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999, 286(5449):2528-2531.
33. Cortez D., Wang Y., Qin J., Elledge S.J. Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 1999, 286(5442):1162-1166.
34. Kastan M.B., Zhan Q., el-Deiry W.S., et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992, 71(4):587-597.
35. Malkin D., Li F.P., Strong L.C., et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990, 250(4985):1233-1238.
36. Savitsky K., Bar-Shira A., Gilad S., et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 1995, 268(5218):1749-1753.
37. Tibbetts R.S., Cortez D., Brumbaugh K.M., et al. Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress. Genes Dev. 2000, 14(23):2989-3002.
38. Wagh P.K., Peace B.E., Waltz S.E. Met-related receptor tyrosine kinase Ron in tumor growth and metastasis. Adv. Cancer Res. 2008, 100:1-33.
39. Stracker T.H., Couto S.S., Cordon-Cardo C., Matos T., Petrini J.H. Chk2 suppresses the oncogenic potential of DNA replication-associated DNA damage. Mol. Cell 2008, 31(1):21-32.
40. Ray D., Terao Y., Fuhrken P.G., et al. Deregulated CDC25A expression promotes mammary tumorigenesis with genomic instability. Cancer Res. 2007, 67(3):984-991.
41. Ray D., Kiyokawa H. CDC25A levels determine the balance of proliferation and checkpoint response. Cell Cycle 2007, 6(24):3039-3042.